Ischemic Reperfusion Injury Clinical Trial
Official title:
Cardio-protective Effect of Metformin in Patients Undergoing Elective Percutaneous Coronary Intervention
Verified date | September 2023 |
Source | Future University in Egypt |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a two-arm randomized parallel study. Patients who will be meeting the above-mentioned criteria and agree to take part in the study, were asked to sign an informed consent prior conducting the study. The whole study protocol were presented to the local institutional review board (IRB).
Status | Active, not recruiting |
Enrollment | 80 |
Est. completion date | December 2024 |
Est. primary completion date | December 9, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult patients (age above 18) - Undergoing elective PCI Exclusion Criteria: 1. Hypersensitivity to metformin or any component of the formulation 2. Patients with current or any history taking metformin either for diabetes mellitus or any other reason such as polycystic ovarian syndrome. 3. Patients diagnosed with type 1 or 2 diabetes mellitus. 4. Any oral or injectable hypoglycemic therapy (e.g. insulin, sulfonylureas) 5. Severe renal dysfunction (eGFR less than 30 mL/minute/1.73 m2 ) from any cause, including shock or septicemia; acute or chronic metabolic acidosis with or without coma (including diabetic ketoacidosis). 6. Treatment with systemic glucocorticoids within 3 months of randomization (due to its potential effect on plasma glucose and HbA1c levels). 7. Metabolic acidosis (total CO 2 below the laboratory lower limit of normal on most recent blood chemistry panel). 8. Need for coronary artery bypass grafting. 9. Participation in other clinical trial in the 30 days before enrollment. 10. The existence of a life-threatening disease with a life-expectancy of less than 6 months. |
Country | Name | City | State |
---|---|---|---|
Egypt | Faculty of Pharmacy, Cairo University | Cairo | |
Egypt | Kasr El Aini Hospital | Cairo | |
Egypt | Kasr El-Aini Hospital | Cairo |
Lead Sponsor | Collaborator |
---|---|
Future University in Egypt | Cairo University, Cairo University Hospitals |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Postprocedural myocardial injury | the occurrence of postprocedural myocardial injury, defined as a postprocedural elevation of CKMB or cTnI more than 1 times the 99 th percentile of the URL [ 24 hours post PCI] | 6 months | |
Secondary | CK-MB | Mean peak values of CK-MB after intervention | 24 hours post PCI | |
Secondary | cTn | Mean peak values of cTnI after intervention | 24 hours post PCI | |
Secondary | LVEF in percent | Echo: to measure LVEF in percent | Baseline- 6 months | |
Secondary | LVMI in g/m2 | left ventricular mass index (LVMI) will be calculated in g/m2 using the sex and body surface area (m²) and measures of LVEDD in mm, IVSd in mm, PWd from the measures in the echocardiography | Baseline- 6 months | |
Secondary | GFR | glomerular filtration rate (GFR) will be calculated (unit ml/min) using age in years, sex, body weight in kilograms and serum creatinine in mg/dL | Baseline- monthly- 6 months | |
Secondary | Serum creatinine (SCr) | Serum creatinine (SCr) in mg/dL | Baseline- monthly- 6 months | |
Secondary | Lactate concentration | lactate concentration unit in mmol/L | Baseline - 6 months | |
Secondary | Glucometabolic State | Glucometabolic State using HbA1c (unit mmols/mol) | Baseline - 6 months | |
Secondary | Incidence of Cardiovascular Event | Cardiovascular events including major cardiac adverse events (MACE; death, recurrent MI, target lesion revascularization), stroke, non-elective hospitalizations for chest pain or heart failure, all recurrent coronary interventions, and internal cardiac defibrillator implantations. Mortality will be divided into cardiac and non- cardiac. Cardiac death will be divided into three categories: heart failure, sudden death, and others. | Baseline - 6 months | |
Secondary | Rate of hospitalization | The number of hospitalizations within each group will be calculated during the study period. | through study completion, an average of 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02134314 -
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
|
Phase 1/Phase 2 | |
Recruiting |
NCT01476969 -
Effect of Remote Ischemic Perconditioning on Acute Kidney Injury in Adult Valve Replace
|
N/A | |
Completed |
NCT03050489 -
Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
|
||
Recruiting |
NCT02940600 -
Efficacy Evaluation of Normothermic Perfusion Machine Preservation in Liver Transplant Using Very Old Donors
|
N/A | |
Recruiting |
NCT02649309 -
Single-cycle Remote Ischemic Preconditioning and Postconditioning (SCRIP) Trial
|
N/A | |
Recruiting |
NCT02729155 -
Single-cycle Remote Ischemic Preconditioning and Postconditioning for Prevention of Contrast-Induced Nephropathy
|
N/A | |
Completed |
NCT02290080 -
Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers
|
Phase 3 | |
Not yet recruiting |
NCT04068116 -
Impact of Ischemic Post-conditioning
|
N/A | |
Terminated |
NCT01726465 -
Methylprednisolone N Acetylcysteine in Hepatic Resections
|
Phase 2 | |
Completed |
NCT03535623 -
RIPC During Free Flap With Preoperative Radiotherapy
|
N/A | |
Completed |
NCT02581618 -
Remote Ischemic Preconditioning in Elective Percutaneous Interventions
|
N/A | |
Recruiting |
NCT04000334 -
Early Transcranial Doppler Goal Directed Therapy After Cardiac Arrest: a Pilot Study
|
N/A | |
Completed |
NCT01887171 -
Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus
|
N/A | |
Recruiting |
NCT05148715 -
Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function (CINERGY)
|
Phase 2 | |
Recruiting |
NCT05661227 -
Mechanism of Cardiac and Cerebral Function Injury Caused by Intraoperative Limb Ischemia-reperfusion
|
N/A | |
Completed |
NCT04257240 -
Recurrence of Liver Malignancy After Ischemia/Reperfusion Injury
|
||
Completed |
NCT05194306 -
PERTRIAL - Perla® Preservation Solution
|
N/A | |
Recruiting |
NCT05179434 -
A Study of Retrograde Reperfusion of Renal Graft to Reduce Ischemic-reperfusion Injury
|
N/A | |
Not yet recruiting |
NCT04951791 -
Lipid Emulsion in Cardiac Valve Replacement Surgery
|
N/A | |
Completed |
NCT01666587 -
Ischemia Reperfusion: Prostaglandins and Antioxidants
|
N/A |